DelSiTech Ltd Receives Funding for the Stabilization of Viral Vaccines

Awarded a grant for vaccine development by the Bill & Melinda Gates Foundation

Turku, Finland – 24 October 2018: DelSiTech Ltd, a Finnish drug delivery and drug development company, today announced significant grant funding to support the development of thermostabilized viral vaccines from the Bill & Melinda Gates Foundation.

DelSiTechTMSilica Matrix is an advanced, sustained and controlled release delivery technology for administration of injectable, implant and topical eye drop dosage forms. One important feature of DelSiTech’s technology is the ability to confer thermostability to viruses over long periods of time, over years.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH